Quick Takeaways
- Matthew Gline has 2 issuer positions tracked on this page.
- Estimated disclosed ownership value: $496,998,031.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Matthew Gline
- Location
- New York, NY
- Summary
- The estimated net worth of Matthew Gline is at least $496,998,031 dollars as of 01 Apr 2026. Matthew Gline is the CEO, Director of Roivant Sciences Ltd. and owns shares of Roivant Sciences Ltd. (ROIV) stock worth about $369.46M. Matthew Gline is the Director, 10%+ Owner of Arbutus Biopharma Corp and owns shares of Arbutus Biopharma Corp (ABUS) stock worth about $127.54M.
- Signature
- By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Matthew Gline and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Roivant Sciences Ltd. ($369,461,813).
- Past-year value change for that position: -$37,673,243.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Matthew Gline
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | CEO, Director | $369,461,813 | -$37,673,243 | -9.3% | 30 Mar 2026 |
| ABUS | Arbutus Biopharma Corp | Director, 10%+ Owner | $127,536,218 | 24 Feb 2025 |
Insider Transactions Reported by Matthew Gline:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.